Des-(N-2-pyridyl-β-alanine Ethyl Ester) Dabigatran Etexilate 5-Ethyl Carboxylate


Product Details

CAT No.# CS-T-16449
Category Impurities
CAS 1408238-36-7
Molecular Weight 479.57
Molecular Formula C26H33N5O4
Purity: >98%
Synonyms: 2-[[[4-[[[(Hexylo]amino]methyl]-1-methyl-1H-benzimidazoleEthyl Ester,Dabigatran Impurity
Application Notes: Des-(N-2-pyridyl-Beta-alanine ethyl ester) Dabigatran etexilate 5-ethyl carboxylate is a derivative of Dabigatran , an oral thrombin inhibitor used to prevent venous thromboembolism. ;Impurity in commercial preparations of Dabigatran
References: Eerenberg, E., et al.: Circulation, 124, 1573 (2011); Eriksson, B., et al.: Lancet, 370, 949 (2007); van Ryn, J., et al.: Thromb. & Haemo., 103, 1116 (2010)
Shipping: Free Shipping for worldwide on order above 2000 USD , Extra charges for Dry ice shipment 80$*
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
Related Results for 'Des-(N-2-pyridyl-β-alanine Ethyl Ester) Dabigatran Etexilate 5-Ethyl Carboxylate'

- API Standards of Dabigatran
- Stable Isotopes of Dabigatran
- Metabolites of Dabigatran
- Impurities of Dabigatran
- Glucuronides of Dabigatran
- Intermediates of Dabigatran

PEOPLE ALSO SEARCHED FOR: 1. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
2. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
3. Benidipine D7
4. Lauroside D
5. Triazolam 13C D3
6. Icatibant impurity 1
8. 0.1% TFA in Water ULC-MS
9. Metamizole EP Impurity C HCl
10. Silodosin Metabolite D4
11. Brivaracetam Carboxylic acid metabolite [UCB 42145]
12. Terbuthylazine D5
13. tibolone (848)
14. (Z)-Dimethylvinphos
15. Silodosin Metabolite
16. 2-Phenoxymethanesulfonanilide
17. Nimesulide EP Impurity A
18. Acetone HPLC
19. Nandrolone Decanoate EP impurity F
20. N-(4-Bromophenyl)-3-methyl-N-(m-tolyl)aniline

This page contains information about Des-(N-2-pyridyl-β-alanine Ethyl Ester) Dabigatran Etexilate 5-Ethyl Carboxylate Cas 1408238-36-7 and its Impurities.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."